Mary E. Godwin Sells 47,031 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin sold 47,031 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $2.87, for a total value of $134,978.97. The sale was disclosed in a filing with the SEC, which is available through this link.

Mary E. Godwin also recently made the following trade(s):

• On Tuesday, September 17th, Mary E. Godwin sold 35,000 shares of Nautilus Biotechnology stock. The stock was sold at an average price of $2.85, for a total value of $99,750.00.

Nautilus Biotechnology Trading Up 1.1 %

Shares of Nautilus Biotechnology stock opened at $2.85 on Friday. Nautilus Biotechnology, Inc. has a 12 month low of $2.19 and a 12 month high of $3.45. The stock’s fifty day moving average price is $2.61 and its 200-day moving average price is $2.60. The firm has a market cap of $357.42 million, a P/E ratio of -5.18 and a beta of 1.20.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. During the same quarter in the prior year, the business posted ($0.13) earnings per share. Analysts forecast that Nautilus Biotechnology, Inc. will post -0.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NAUT shares. Jefferies Financial Group started coverage on shares of Nautilus Biotechnology in a report on Monday, June 3rd. They set a “hold” rating and a $3.00 price objective for the company. Guggenheim started coverage on Nautilus Biotechnology in a report on Thursday, June 27th. They issued a “buy” rating and a $6.00 price target for the company.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently bought and sold shares of NAUT. Price T Rowe Associates Inc. MD increased its holdings in shares of Nautilus Biotechnology by 35.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after acquiring an additional 4,239 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Nautilus Biotechnology by 66.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock valued at $71,000 after purchasing an additional 9,624 shares in the last quarter. Renaissance Technologies LLC grew its stake in Nautilus Biotechnology by 11.2% in the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after purchasing an additional 14,100 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Nautilus Biotechnology by 19.8% in the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock worth $1,345,000 after purchasing an additional 94,908 shares in the last quarter. Finally, Clarius Group LLC lifted its position in shares of Nautilus Biotechnology by 2.7% during the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock valued at $1,489,000 after buying an additional 16,661 shares during the last quarter. Hedge funds and other institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.